Browse News
Filter News
Found 261 articles
-
Cell-Free RNA Isolation and Extraction Kits Market Reach USD123.94 Million by 2031
4/17/2024
Global Cell-Free RNA Isolation & Extraction Kits Market is valued at US$ 41.55 Mn in 2023, and it is expected to reach US$ 123.94 Mn by 2031, with a CAGR of 14.90% during the forecast period of 2024-2031.
-
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
4/15/2024
TFF Pharmaceuticals, Inc. announced additional positive data from the ongoing Phase 2 study which is evaluating Tacrolimus Inhalation Powder for the prevention of organ rejection in lung transplant recipients.
-
Single-use Bioprocessing Market Size to Increase USD 128.24 Bn by 2033
4/9/2024
According to Nova One Advisor, the global single-use bioprocessing market size was estimated at USD 28.45 billion in 2023 and it is projected to increase USD 128.24 billion by 2033 with a CAGR of 16.25% from 2024 to 2033.
-
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
3/28/2024
TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, reported financial results for the fourth quarter and full year 2023.
-
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
3/27/2024
TFF Pharmaceuticals, Inc. announced updated data from the Tacrolimus Inhalation Powder and Voriconazole Inhalation Powder clinical programs.
-
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC)
3/25/2024
TFF Pharmaceuticals, Inc. today announced the acceptance of its late-breaking clinical science abstract for oral presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting.
-
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
3/22/2024
TFF Pharmaceuticals, Inc, announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 147,500 shares of common stock at a purchase price of $8.00 per share.
-
TFF Pharmaceuticals Announces Update on Clinical Programs
3/20/2024
TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, is announcing data updates and strategic prioritization of its clinical programs.
-
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
3/20/2024
TFF Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, announced that it has entered into definitive agreements for the purchase and sale of 147,500 shares of common stock at a purchase price of $8.00 per share in a registered direct offering priced at-the-market under Nasdaq rules.
-
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
3/14/2024
TFF Pharmaceuticals, Inc. announced that Harlan Weisman, M.D., Chief Executive Officer of TFF Pharmaceuticals will be presenting a corporate overview at the 36th Annual Roth Conference being held March 17-19, 2024 in Dana Point, California.
-
Aileron Therapeutics Announces CEO Transition
3/12/2024
Aileron Therapeutics, Inc. today announced that current President and Chief Operating Officer, Brian Windsor, Ph.D., has been appointed President and Chief Executive Officer (CEO) and will join the Board of Directors, effective March 11, 2024.
-
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
2/21/2024
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023.
-
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
2/15/2024
Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced that its Chairman and Chief Executive Officer, Lishan Aklog, M.D., highlighted Lucid's EsoCheck® Cell Collection Device during testimony before the U.S. House of Representatives' Committee on Small Business.
-
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference
1/24/2024
TFF Pharmaceuticals, Inc. today announced that the Company will present data from the Phase 2 trial of Voriconazole Inhalation Powder (TFF VORI) for the treatment of invasive pulmonary aspergillosis at the upcoming Advances Against Aspergillosis & Mucormycosis (AAAM) Conference, which will be held from January 25-27, 2024, in Milan, Italy.
-
TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
1/9/2024
TFF Pharmaceuticals, Inc. announced the acceptance of a late-breaking abstract for presentation at the 44th Annual International Society for Heart and Lung Transplantation 2024 Meeting, which will be held in Prague, Czech Republic from April 10-13, 2024.
-
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
12/19/2023
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) today announced positive initial data from the Company’s ongoing Phase 2 trials of TFF VORI and TFF TAC, along with clinical data from the ongoing TFF VORI Expanded Access Program (EAP).
-
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC
12/18/2023
TFF Pharmaceuticals, Inc. announced that the Company will hold a conference call and webcast to review initial data from the ongoing Phase 2 trials of TFF VORI and TFF TAC on Tuesday, December 19th at 8:30 am ET.
-
TFF Pharmaceuticals Announces Reverse Stock Split
12/15/2023
TFF Pharmaceuticals, Inc. announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares.
-
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors
12/13/2023
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors.
-
TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors
11/30/2023
TFF Pharmaceuticals, Inc. today announced the appointment of Michael Patane, Ph.D., to its Board of Directors.